The invention features a method of producing aggregates of a plurality of cell populations (e.g., a first population of cells and a second population of cells). The method includes agitating a liquid medium that contains the cells in a bioreactor. These aggregates may be used for subsequent downstream applications, such as encapsulation in a biocompatible scaffold to form an engineered tissue construct.

The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34.sup.+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34.sup.+ cells and then a co-culture of a CD34.sup.+ cells with CD34.sup.+-derived endothelial cells within a biomimetic gel.

A hybrid tissue scaffold is provided which comprises a porous primary scaffold having a plurality of pores and a porous secondary scaffold having a plurality of pores, wherein the secondary scaffold resides in the pores of the primary scaffold to provide a hybrid scaffold. The pores of the porous primary scaffold may have a pore size in a range of 0.50 mm to 5.0 mm, and the pores of the porous secondary scaffold may have a pore size in a range of 50 m to 600 m. The primary scaffold may provide 5% to 30% of a volume of the hybrid scaffold.

A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stern cells for treating fistulae.

Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

Structures and methods for tissue engineering include a multicellular body including a plurality of living cells. A plurality of multicellular bodies can be arranged in a pattern and allowed to fuse to form an engineered tissue. The arrangement can include filler bodies including a biocompatible material that resists migration and ingrowth of cells from the multicellular bodies and that is resistant to adherence of cells to it. Three-dimensional constructs can be assembled by printing or otherwise stacking the multicellular bodies and filler bodies such that there is direct contact between adjoining multicellular bodies, suitably along a contact area that has a substantial length. The direct contact between the multicellular bodies promotes efficient and reliable fusion. The increased contact area between adjoining multicellular bodies also promotes efficient and reliable fusion. Methods of producing multicellular bodies having characteristics that facilitate assembly of the three-dimensional constructs are also provided.

The present invention relates to a method for culturing hair follicle-derived stem cells and uses thereof, particularly to a method for culturing hair follicle-derived stem cells; hair follicle-derived stem cells prepared by the method; and a pharmaceutical composition for hair loss treatment or hair growth promotion; a quasi-drug composition; and a cosmetic composition, which contains the prepared hair follicle-derived stem cells, a culture of the hair follicle-derived stem cells, or cells differentiated from the hair follicle-derived stem cells as an active ingredient.

According to the culture method of the present invention, stem cells can be effectively isolated and obtained from hair follicle tissue, and the obtained hair follicle-derived stem cells have excellent pluripotency and self-replication ability as well as excellent hair loss treatment and hair growth promotion effects and can be usefully utilized for hair loss improvement, prevention, or treatment.